Switch to: Citations

Add references

You must login to add references.
  1. The Impact of HIV Infection on Society's Perception of Clinical Trials.Robert J. Levine - 1994 - Kennedy Institute of Ethics Journal 4 (2):93-98.
    All international codes of research ethics and virtually all national legislation and regulation in the field of research involving human subjects project an attitude of protectionism. Written with the aim of avoiding a repetition of atrocities like those committed by the Nazi physician-researchers, calamities like the thalidomide experience, or ethical violations like those of the Tuskegee syphilis study, their dominant concerns are the protection of individuals from injury and from exploitation. In recent years, however, society's perception of clinical research has (...)
    Download  
     
    Export citation  
     
    Bookmark   10 citations  
  • Genetic Research as Therapy: Implications of “Gene Therapy” for Informed Consent.Larry R. Churchill, Myra L. Collins, Nancy M. P. King, Stephen G. Pemberton & Keith A. Wailoo - 1998 - Journal of Law, Medicine and Ethics 26 (1):38-47.
    In March 1996, the General Accounting Office issued the report Scientific Research: Continued Vigilance Critical to Protecting Human Subjects. It stated that “an inherent conflict of interest exists when physician-researchers include their patients in research protocols. If the physicians do not clearly distinguish between research and treatment in their attempt to inform subjects, the possible benefits of a study can be overemphasized and the risks minimized.” The report also acknowledged that “the line between research and treatment is not always clear (...)
    Download  
     
    Export citation  
     
    Bookmark   9 citations  
  • Experimental Treatment Oxymoron or Aspiration?Nancy M. P. King - 1995 - Hastings Center Report 25 (4):6-15.
    Giving up the increasingly troubled distinction between “experiment” and “treatment” would make it easier to focus on informed consent and harder to beg questions about uncertainty and shared decisionmaking in medicine.
    Download  
     
    Export citation  
     
    Bookmark   10 citations  
  • False Hopes and Best Data: Consent to Research and the Therapeutic Misconception.Paul S. Appelbaum, Loren H. Roth, Charles W. Lidz, Paul Benson & William Winslade - 1987 - Hastings Center Report 17 (2):20-24.
    Download  
     
    Export citation  
     
    Bookmark   161 citations  
  • (1 other version)Defining and Describing Benefit Appropriately in Clinical Trials.Nancy M. P. King - 2000 - Journal of Law, Medicine and Ethics 28 (4):332-343.
    Institutional review boards and investigators are used to talking about risks of harm. Both low risks of great harm and high risks of small harm must be disclosed to prospective subjects and should be explained and categorized in ways that help potential subjects to understand and weigh them appropriately. Everyone on an IRB has probably spent time at meetings arguing over whether a three-page bulleted list of risk description is helpful or overkill for prospective subjects. Yet only a small fraction (...)
    Download  
     
    Export citation  
     
    Bookmark   67 citations  
  • What Patients Say about Medical Research.Jeremy Sugarman, Nancy E. Kass, Steven N. Goodman, Patricia Perentesis, Praveen Fernandes & Ruth R. Faden - 1998 - IRB: Ethics & Human Research 20 (4):1.
    Download  
     
    Export citation  
     
    Bookmark   11 citations